Oro-mandibular dystonia developing with both sertraline and fluoxetine use in a female adolescent with major depressive disorder
Yükleniyor...
Dosyalar
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Yerküre Tanıtım ve Yayıncılık Hizmetleri A.Ş.
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Oro-mandibular dystonia (OMD) involves repetitive uncontrollable contractions of the lower facial muscles (Scorr et al. 2021). Its etiology is not fully elucidated although various neurological (encephalitis, etc.), psychogenic and psychopharmacological (SSRIs, antipsychotics etc.) causes were implicated (Kutuk et al. 2019, Scorr et al. 2021). The odds ratio (OR) is 1.7 for dystonia in general after using SSRIs (Revet et al. 2020). Paroxetine (OR= 1.7) and fluoxetine (OR= 1.5) have the highest risks among SSRIs while escitalopram has the lowest (OR=0.8, Revet et al. 2020). Adolescent patients developing OMD after treatment with sertraline or fluoxetine alone were reported previously (Kutuk et al. 2019, Revet et al. 2020). However, OMD in a patient with sequential trials of different SSRIs are not reported up to now.
Açıklama
Anahtar Kelimeler
Oro-Mandibular Dystonia, Fluoxetine, Sertraline, Major Depressive Disorder
Kaynak
Psychiatry and Behavioral Sciences
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
12
Sayı
4
Künye
Sarioglu, S., Ali, E. T., Ozturk, Y., & Ozdemir, D. (2022). Oro-Mandibular Dystonia Developing with both Sertraline and Fluoxetine Use in a Female Adolescent with Major Depressive Disorder. Psychiatry and Behavioral Sciences, 12(4), 210.
